SCHEMBL6426519

SCHEMBL6426519

Cc1c([C@H](CC2CCCC2)C(=O)O)c2c(F)c(O)ccc2n1C(=O)c1cccc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HTT P42858 2/20 0.37
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
EPHX2 P34913 1/20 0.34
USP2 O75604 1/20 0.34
PIK3CD O00329 1/20 0.33
USP30 Q70CQ3 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6424262 0.98 AKR1C3 (0.36) TDP1KDM4EHTTAKR1C3AKR1C2
SCHEMBL6426870 0.91 METAP2 (0.36) KDM4EAKR1C3AKR1C2ALDH1A1MEN1
SCHEMBL6424977 0.89 TDP1 (0.36) TDP1KDM4EHTTAKR1C3AKR1C2
SCHEMBL6426850 0.89 USP30 (0.33) AKR1C3AKR1C2LMNAMEN1KMT2A
SCHEMBL6428226 0.87 TSHR (0.34) AKR1C3AKR1C2ALDH1A1HPGDTSHR
SCHEMBL6425046 0.87 USP2 (0.35) TDP1KDM4EHTTAKR1C3AKR1C2
SCHEMBL6424324 0.87 MEN1 (0.32) AKR1C3AKR1C2LMNAMEN1KMT2A
SCHEMBL6464700 0.86 PTGS2 (0.33) AKR1C3AKR1C2
SCHEMBL6426717 0.86 AKR1C3 (0.40) KDM4EHTTAKR1C3AKR1C2ALDH1A1
SCHEMBL6426451 0.86 AKR1C3 (0.40) KDM4EHTTAKR1C3AKR1C2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 TDP1 3450/4885KDM4E 2209/4885HTT 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.